Source: Food Business News

Specialty Enzymes & Biotechnologies: GRAS status of spore-forming probiotic receives FDA 'no questions' letter

The ingredient survives the journey to the gut.

Read full article »
Specialty Enzymes & Biotechnologies's Competitors | Specialty Enzymes & Biotechnologies's News | Specialty Enzymes & Biotechnologies's Financials
Stay up-to-date with the latest news on SEB
Est. Annual Revenue
$100-500M
Est. Employees
100-250
Vic Rathi's photo - President & CEO of SEB

President & CEO

Vic Rathi

CEO Approval Rating

81/100

Read more
Stay up-to-date with the latest news on SEB